Replies to post #50250 on NorthWest Biotherapeutics Inc (NWBO)

[beachlifeisfun]

So I am left wondering what factors are contributing to the longer PFS of the placebo patients in NWBO's trial and what impact this will have with regard to the comparison of PFS in the treatment vs. control groups?--ready4bluesky

I am confused...LL said that everyone in the trial is living longer...she didn't say anything about PFS for the P3. But I think that you are aware of this. I have mentioned this to you and others in the past...I expect that both placebo and experimental patients will have a longer OS due to the crossover option. This is further evidenced by the results of the information arm. I believe that this is the trend that LL is alluding to. Stop try to twist this very positive information. You almost sound like another individual that used to post here and twist a facts into fiction...

[CaptainObvious]

The fact that everyone eventually receives DCVax may explain it

[Rkmatters]

When they designed this study, they assumed median survival times of 17 and 34 months among patients in the placebo and treatment cohorts. In the video, Linda Liau stated that the median survival for the disease is now closer to 2 years. It would seem to me that they calculated too low of a median for control. In addition to that DCVax-L therapy does affect the crossover, and will affect eventing for that group, one would hope. So yes, control is eventing later. Other factors as to why the placebo group is seeing longer survival has to do with tumor load, and patient selection factors. To understand more, you can see my post. Only difference in my view from my post to now, is that it was explained to me that statistical significance for the PFS doesn't mean it needs to be a flat 4 months. I'm also giving more weight to OS, as I do think that QoL factors can lift a lagging PFS if it fails to show statistical significance.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118808102